Topic Highlight
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jan 14, 2016; 22(2): 776-789
Published online Jan 14, 2016. doi: 10.3748/wjg.v22.i2.776
Table 2 Recent experimental studies of targeted therapy for pancreatic cancer
Targeted therapeuticsRef.Cell lines (cell type)Main results
Multikinase inhibitors
ForetinibChen et al[32]Panc-1(P)Foretinib inhibited tumor growth, angiogenesis and lymphangiogenesis in xenograft animals, by inhibiting c-MET but VEGFR-2, VEGFR-3, and TIE-2 signaling
SKLB261Pan et al[80]BxPC-3 (P),Application of SKLB261 resulted in more potent antitumor activities than dasatinib, gemcitabine, or erlotinib in pancreatic cancer xenografts
Panc-1 (P),
AsPC-1 (S), HPAC (P)
NintedanibAwasthi et al[81]AsPC-1 (S),A triple angiokinase inhibitor, nintedanib inhibited growth of pancreatic cancer cell lines, with gemcitabine enhancing inhibitory effects
BxPC-3 (P),
Panc-1 (P),
MIA-PaCa-2 (P),
Dual inhibition
Lapatinib and trametinibLindberg et al[101]MAD 08-608, 08-738, 09-366 (P)Dual anti-EGFR and anti-HER2 therapy significantly enhanced the growth inhibitory effects of the MEK1/2 inhibitor trametinib
ZSTK474 and RO5126766Van Dort et al[99]Panc-1 (P)PI3K inhibitor and the Raf/MEK inhibitor RO5126766 resulted in high in vitro inhibition of both PI3Kand MEK1 also decreased cellular viability in pancreatic cancer cell line
NVP-AEW541 and lapatinibUrtasun et al[42]NP-9, -18, -29 (P)Combined treatment with the IGF-IR and EGFR/Her-2 inhibitors synergistically inhibited pancreatic cancer cell growth which is associated with abolishment of Akt, Efk, and IRS-1 activity
CP15T, ,15A (p)
Novel pathways
PX-478 (HIF-a)Zhao et al[84]CFPAC-1 (S), BxPC-3 (P),Combined treatment with gemcitabine/PX-478 significantly enhanced the anti-tumor effect which is associated with immunogenic cell death
Panc-1 (P),
MIA-PaCa-2 (P)
SB216763(GSK-3b)Marchand et al[86]Panc-1 (P),Inhibition of GSK-3βn induced apoptosis by mechanism involving JNK-cJUN activation
MIA-PaCa-2 (P), BxPC-3 (P)
Micro RNA
miR-142-3pMacKenzie et al[95]MIA-PaCa-2 (P), Capan-1(S),A unique HSP70 inhibiting compounds, miR-142-3p regulate triptolide-induced inhibition of pancreatic cancer growth
HEK-293 (P),
S2-013 (P)
miR-146aLi et al[96]AsPC-1 (s),miR-146a takes significant roles in pancreatic cancer invasion and metastasis but lower expressed in pancreatic cancer compared with normal pancreatic tissue
Panc-1 (P)
miR-494Li et al[97]Colo357 (s),miR-494, identified to affect levels of FOXM1 in pancreatic cancer cell lines and act as a negative regulator of this transcriptional activator, blocked nuclear translocation β-catenin
Panc-1 (P)